Response to the Letter from Ms. Tamzin Furtado  by Two, Rebecca et al.
Response to the Letter from Ms.Tamzin Furtadovhe_716 508
To the Editor—We are grateful for Ms. Furtado’s letter and
welcome the opportunity to reply regarding this important topic.
We fully agree with Ms Furtado’s point that there is no single
right way to approach the need for translations in multiple
countries sharing a language. We also agree that creating a global
translation is not always ideal and entails a certain amount of
compromise; these are points we touched on in the article [1].
The article does not claim to provide a superior methodology
in terms of producing the “best wording for each individual
country” but explains that some clients speciﬁcally request global
translations, and in cases where this requirement needs to be met,
we have found our methodology to be very effective. The refer-
ence to a “superior ﬁnal translation” was not intended to imply
that the results would be superior to that of other translation
procedures; the paragraph explains that the process we followed
aims to improve the quality of the translation at every stage,
thereby resulting in a ﬁnal translation that is much improved
from the initial draft.
Ms. Furtado asserts that the time and cost involved in holding
teleconferences would “heavily inﬂuence the budget of a project”
and suggests instead appointing a lead investigator and discuss-
ing their wording suggestions with the other investigators via
e-mail. In practice, we have found teleconferences to provide a
fast and efﬁcient way of thoroughly discussing linguistic issues;
within the space of a single call, all queries can be fully discussed
and resolved, allowing simultaneous and equal input from all
target countries. Although e-mails can be used effectively to
resolve straightforward issues, several rounds of e-mails may be
required before a solution is universally agreed upon for more
complex items, thereby affecting the timeline of the project. In
addition, it may prove more difﬁcult to have a full, in-depth
discussion (between several parties) via e-mail. Therefore, a tele-
conference or other form of live conversation is not only likely to
cut time (possibly by several days, depending on how long the
exchange of e-mails would take) but also allows for a freer and
more thorough exchange of ideas. In addition, we have found
that teleconferences add very little to the study budget and can be
even more cost-effective for a sponsor than several rounds of
e-mail–based reviews.
We would welcome a study comparing the merits of our
methodology for producing global translations to those of one
involving a lead investigator as suggested by Ms. Furtado. We
agree that there is currently no “gold standard” approach;
however, our article has presented a real-world application of our
recommended methodology, which we found to be highly effec-
tive in its goals. It may be that a methodology involving a lead
investigator would be equally effective, but it should be recog-
nized that this also has drawbacks, not least the decision in
selecting who should be the lead investigator. For example, if a
Spanish translation is required for several countries in South
America, which country should the lead investigator be chosen
from, or is the choice simply arbitrary?
Once again, we thank Ms. Furtado for continuing this inter-
esting debate and look forward to its development in the
future.—Rebecca Two, BA, Aneesa Verjee-Lorenz, MSc, and
Darren Clayson, MSc, PharmaQuest Ltd., Oxfordshire, UK;
Mehul Dalal, PhD, and Kelly Grotzinger, PhD, GlaxoSmithKline,
Collegeville, PA, USA; and Zobair M. Younossi, MD, MPH,
FACP, FACG, Inova Fairfax Hospital—Center for Liver Diseases,
Falls Church, VA, USA.
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